NO20032425L - Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former - Google Patents

Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former

Info

Publication number
NO20032425L
NO20032425L NO20032425A NO20032425A NO20032425L NO 20032425 L NO20032425 L NO 20032425L NO 20032425 A NO20032425 A NO 20032425A NO 20032425 A NO20032425 A NO 20032425A NO 20032425 L NO20032425 L NO 20032425L
Authority
NO
Norway
Prior art keywords
forms
new
preparing
processes
preparation
Prior art date
Application number
NO20032425A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032425D0 (no
Inventor
Judith Aronhime
Ramy Lidor-Hadas
Valerie Niddam
Revital Lifshitz
Eti Ishai
Guy Sambursky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27540285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032425(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20032425D0 publication Critical patent/NO20032425D0/no
Publication of NO20032425L publication Critical patent/NO20032425L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20032425A 2000-11-30 2003-05-28 Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former NO20032425L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25007200P 2000-11-30 2000-11-30
US26789701P 2001-02-09 2001-02-09
US28187201P 2001-04-05 2001-04-05
US31214401P 2001-08-13 2001-08-13
US32652901P 2001-10-01 2001-10-01
PCT/US2001/044636 WO2002043732A1 (en) 2000-11-30 2001-11-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Publications (2)

Publication Number Publication Date
NO20032425D0 NO20032425D0 (no) 2003-05-28
NO20032425L true NO20032425L (no) 2003-07-25

Family

ID=27540285

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032425A NO20032425L (no) 2000-11-30 2003-05-28 Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former

Country Status (23)

Country Link
US (15) US20020183378A1 (bg)
EP (5) EP1363621A4 (bg)
JP (2) JP2004514694A (bg)
KR (1) KR100765871B1 (bg)
CN (1) CN1489463A (bg)
AU (1) AU2002217927A1 (bg)
BG (1) BG107856A (bg)
BR (1) BR0115892A (bg)
CA (3) CA2689915A1 (bg)
CZ (1) CZ20031766A3 (bg)
DE (1) DE01998348T1 (bg)
ES (2) ES2215495T1 (bg)
HR (2) HRP20030523A2 (bg)
HU (1) HUP0600538A3 (bg)
IL (2) IL156055A0 (bg)
IS (1) IS6829A (bg)
MX (1) MXPA03004844A (bg)
NO (1) NO20032425L (bg)
PL (1) PL363228A1 (bg)
SK (1) SK8062003A3 (bg)
TR (1) TR200400815T3 (bg)
WO (1) WO2002043732A1 (bg)
YU (1) YU42803A (bg)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36268E (en) * 1988-03-15 1999-08-17 Boehringer Mannheim Corporation Method and apparatus for amperometric diagnostic analysis
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CZ20031495A3 (cs) * 2000-11-03 2004-01-14 Teva Pharmaceutical Industries Ltd. Forma VII hemi-kalcium atorvastatinu
MXPA03004276A (es) * 2000-11-16 2005-04-29 Teva Pharma Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio.
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156280A0 (en) 2000-12-27 2004-01-04 Ciba Sc Holding Ag Crystalline forms of atorvastatin
CA2450111C (en) * 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP1414796A1 (en) * 2001-07-30 2004-05-06 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
MXPA04001451A (es) * 2001-08-16 2005-02-17 Teva Pharma Procesos para preparar formas de sal de calcio de estatinas.
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
AU2003217653A1 (en) * 2002-02-15 2003-09-09 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
EP1465901A4 (en) * 2002-02-19 2006-02-01 Teva Pharma PROCESS FOR THE DESOLVATION OF ATORVASTATIN HEMI-CALCIUM SOLVATES AND OF ESSENTIALLY SOLVENT-FREE ATORVASTATIN HEMI-CALCIUM
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004022053A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
PL1727795T3 (pl) 2004-03-17 2012-06-29 Ranbaxy Laboratories Ltd Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
US20080262074A1 (en) * 2004-05-24 2008-10-23 Pfizer, Inc. Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2573771C (en) 2004-07-20 2011-05-10 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
DE05800195T1 (de) * 2004-09-28 2006-12-28 Teva Pharmaceutical Industries Ltd. Verfahren zur Herstellung von Atorvastatin-Calcium, die im wesentlichen frei von Verunreinigungen sind
KR20070106680A (ko) * 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
EP1716114A1 (en) * 2004-10-18 2006-11-02 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
RU2007115543A (ru) 2004-10-28 2008-12-10 Уорнер-Ламберт Компани Эл-Эл-Си (US) Способ получения аморфного аторвастатина
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
JP5523699B2 (ja) * 2005-04-08 2014-06-18 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ 新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
WO2007057755A1 (en) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
KR20100023059A (ko) * 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
JP2007246514A (ja) * 2006-02-14 2007-09-27 Toyama Chem Co Ltd ピペラシリンナトリウムの新規な結晶
AU2007219107B2 (en) * 2006-02-22 2012-12-06 Mylan Laboratories Ltd. New crystalline form of Atorvastatin hemi-calcium
US20070249845A1 (en) * 2006-03-01 2007-10-25 Michael Pinchasov Process for preparing a crystalline form of atorvastatin hemi-calcium
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
TW200811101A (en) * 2006-07-14 2008-03-01 Ranbaxy Lab Ltd Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
AU2007300071A1 (en) * 2006-09-27 2008-04-03 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR20090104855A (ko) * 2007-01-31 2009-10-06 토야마 케미칼 컴퍼니 리미티드 피페라실린나트륨의 신규 결정
RU2421445C1 (ru) 2007-03-02 2011-06-20 Донг-А Фарм. Ко., Лтд. Новые кристаллические формы производных пирролилгептановой кислоты
WO2008129562A2 (en) * 2007-04-20 2008-10-30 Morepen Laboratories Limited An improved process for the preparation of stable amorphous atorvastatin hemi calcium and their salts thereof
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法
WO2009082362A1 (en) * 2007-11-05 2009-07-02 Ulkar Kimya San. Ve Tic. A.S. A method for producing statins in pure form
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101538237B (zh) * 2008-05-30 2011-04-06 天津和美生物技术有限公司 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用
US8685173B2 (en) 2008-07-17 2014-04-01 Delaval Holding Ab Method of cleaning food and beverage manufacturing and handling equipment
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
US11473032B2 (en) 2010-02-02 2022-10-18 Fuchs Petrolub Se Constant velocity joint having a boot
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN102766136A (zh) * 2012-08-07 2012-11-07 浙江宏元药业有限公司 一种制备阿托伐他汀钙中间体的方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
CN103641764B (zh) * 2013-11-25 2015-12-02 北京三泉医药技术有限公司 调节血脂的药物组合物
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN104983690A (zh) * 2015-08-18 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂
EP3272336A1 (de) * 2016-07-19 2018-01-24 Stada Arzneimittel Ag Atorvastatin-zusammensetzung

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115709A (en) * 1871-06-06 Improvement in curriers slickers
US99224A (en) * 1870-01-25 Improvement in pocket-sates for friction-matches
US2598627A (en) * 1949-10-11 1952-05-27 Robert Gair Co Inc Folding carton
DE2748825C2 (de) * 1976-11-02 1986-11-27 Sankyo Co., Ltd., Tokio/Tokyo Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
SG45369A1 (en) * 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4411536A1 (de) * 1994-04-02 1995-10-05 Cassella Ag Wasserquellbare hydrophile Polymere
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
MX9709099A (es) * 1995-07-17 1998-02-28 Warner Lambert Co Sal hemi calcio de acido [r-r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metil etil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrole-1-heptanoi co (atorvastatin).
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6065729A (en) * 1998-01-28 2000-05-23 Prince Corporation Slide-out container holder
US5959156A (en) 1998-11-12 1999-09-28 Bp Amoco Corporation Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (bg) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI1235799T1 (en) * 1999-11-17 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
MXPA02004082A (es) 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso para producir calcio de atorvastatin cristalino.
IL149087A0 (en) 1999-12-17 2002-11-10 Warner Lambert Res & Dev Ie A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium
CZ20031495A3 (cs) * 2000-11-03 2004-01-14 Teva Pharmaceutical Industries Ltd. Forma VII hemi-kalcium atorvastatinu
MXPA03004276A (es) * 2000-11-16 2005-04-29 Teva Pharma Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio.
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156280A0 (en) * 2000-12-27 2004-01-04 Ciba Sc Holding Ag Crystalline forms of atorvastatin
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (bg) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CA2450111C (en) 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP1414796A1 (en) 2001-07-30 2004-05-06 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
MXPA04001451A (es) * 2001-08-16 2005-02-17 Teva Pharma Procesos para preparar formas de sal de calcio de estatinas.
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
CA2467691A1 (en) 2001-11-30 2004-01-29 University Of Maryland, Baltimore Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
AU2003217653A1 (en) 2002-02-15 2003-09-09 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
EP1465901A4 (en) 2002-02-19 2006-02-01 Teva Pharma PROCESS FOR THE DESOLVATION OF ATORVASTATIN HEMI-CALCIUM SOLVATES AND OF ESSENTIALLY SOLVENT-FREE ATORVASTATIN HEMI-CALCIUM
EP1488315A2 (en) 2002-03-28 2004-12-22 Emc Corporation Data storage system
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
WO2004022053A1 (en) 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
EP1572643A2 (en) 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
EP1716114A1 (en) * 2004-10-18 2006-11-02 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i

Also Published As

Publication number Publication date
EP2192112B1 (en) 2013-08-28
EP1363621A4 (en) 2005-12-28
EP1783113A2 (en) 2007-05-09
CN1489463A (zh) 2004-04-14
CZ20031766A3 (cs) 2004-08-18
HUP0600538A3 (en) 2010-09-28
US7256212B2 (en) 2007-08-14
ES2437157T3 (es) 2014-01-09
EP2192113A1 (en) 2010-06-02
BR0115892A (pt) 2003-10-28
DE01998348T1 (de) 2004-08-26
US6992194B2 (en) 2006-01-31
US7488750B2 (en) 2009-02-10
HRP20030523A2 (en) 2005-06-30
US7456297B2 (en) 2008-11-25
MXPA03004844A (es) 2005-04-19
KR100765871B1 (ko) 2007-10-11
CA2689915A1 (en) 2002-06-06
US20060106231A1 (en) 2006-05-18
US20060100446A1 (en) 2006-05-11
EP2192112A1 (en) 2010-06-02
ES2215495T1 (es) 2004-10-16
CA2625277A1 (en) 2002-06-06
IL156055A0 (en) 2003-12-23
YU42803A (sh) 2006-05-25
US20060100267A1 (en) 2006-05-11
IL156055A (en) 2010-12-30
US20050090542A1 (en) 2005-04-28
US20020183378A1 (en) 2002-12-05
SK8062003A3 (en) 2004-07-07
TR200400815T3 (tr) 2004-07-21
JP2004514694A (ja) 2004-05-20
JP2009120624A (ja) 2009-06-04
IS6829A (is) 2003-05-27
NO20032425D0 (no) 2003-05-28
EP1783113A3 (en) 2007-05-30
EP1363621A1 (en) 2003-11-26
US7468444B2 (en) 2008-12-23
US20050261359A1 (en) 2005-11-24
US20050004206A1 (en) 2005-01-06
US20060058533A1 (en) 2006-03-16
US20060100445A1 (en) 2006-05-11
AU2002217927A1 (en) 2002-06-11
US20060106232A1 (en) 2006-05-18
US7161012B2 (en) 2007-01-09
US20080214650A1 (en) 2008-09-04
EP2194041A1 (en) 2010-06-09
US7342120B2 (en) 2008-03-11
BG107856A (bg) 2004-11-30
CA2429590C (en) 2008-06-10
US20050267198A1 (en) 2005-12-01
US7151183B2 (en) 2006-12-19
US7144916B2 (en) 2006-12-05
KR20030059297A (ko) 2003-07-07
US20050261361A1 (en) 2005-11-24
HUP0600538A2 (en) 2006-09-28
US20050261360A1 (en) 2005-11-24
CA2429590A1 (en) 2002-06-06
US7189861B2 (en) 2007-03-13
PL363228A1 (en) 2004-11-15
US20050282885A1 (en) 2005-12-22
WO2002043732A1 (en) 2002-06-06
HRP20130545A2 (hr) 2013-11-08

Similar Documents

Publication Publication Date Title
NO20032425L (no) Nye krystallformer av atorvastatin-hemikalsium og fremgangsmater for deresfremstilling, sa vel som nye fremgangsmater for fremstilling avandre former
IS7188A (is) Asabísýklísk-setin samtengd heteróarýl efnasambönd, aðferð til framleiðslu þeirra og notkun
NO20041994L (no) Nye beta-fenyl-alfa-oksysubstituerte propion derivater: Fremgangsmate for deres fremstilling og deres anvendelse ved fremstilling av farmasoytisk riktige forbindelser
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
NO20043842L (no) Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
DK1381605T3 (da) Mercaptoacetylamidderivater, en fremgangsmåde til deres fremstilling og deres anvendelse
NO20024623L (no) Ny fremgangsmÕte for fremstilling av kondensert imidazopyridinderivat og ny krystallform
NO20023400D0 (no) Nye forbindelser med lipid- og kolesterolnedsettende virkning, fremgangsmåte ved deres fremstilling og farmasöytiskpreparat
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
NO20010522L (no) Nye piperidin-4-sulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
NO20023662D0 (no) Nye heterocykliske derivater, fremgangsmåte ved fremstilling og farmasöytiske sammensetninger inneholdende det samme
NO20016389D0 (no) Fremgangsmåte for fremstilling av substituerte cyklopentanderivater og nye krystallinske strukturer derav
NO20026154D0 (no) Nye substituerte ftalider, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20035633D0 (no) Teknisk syntesemetode for fremstilling av tropenol
NO20013735D0 (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
NO20031844D0 (no) Nye askorbinsyreforbindelser, syntesemetoder og anvendelse derav
IS7008A (is) Nýjar píperidínkarboxamíð afleiður, aðferð til framleiðslu þeirra og lyfjasamsetningar sem innihalda þær
NO20031108L (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
NO20016069L (no) Nye bicykliske amino-pyrazinonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
NO20044332L (no) Forbedret fremgangsmate for fremstilling av nevirapine
NO20033743L (no) Fremgangsmåte og fremstilling citalopram
NO20020308D0 (no) Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten
NO20023577L (no) Fremgangsmåte for fremstilling av acetyl-amidinofenylalanyl- cykloheksylglycyl-pyridinioalaninamider
EA200300771A1 (ru) Новая соль бензоилгуанидина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application